Protagonist Therapeutics, Inc Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Protagonist Therapeutics, Inc (PTGX) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 1.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-02-25
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 1.70%.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.10%, a 125.00% decline from fiscal 2023.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.40%.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -2.70%, a 437.50% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 1.70% 10-K · filed 2026-02-25 | |
| 2024-12-31 | -0.10% 10-K · filed 2026-02-25 | -0.50% 10-K · filed 2025-02-21 |
| 2023-12-31 | 0.40% 10-K · filed 2026-02-25 | -3.40% 10-K · filed 2024-02-27 |
| 2022-12-31 | -2.70% 10-K · filed 2025-02-21 | |
| 2021-12-31 | 0.80% 10-K · filed 2024-02-27 | |
| 2020-12-31 | 3.80% 10-K · filed 2023-03-15 | |
| 2019-12-31 | -2.50% 10-K · filed 2022-02-28 | |
| 2018-12-31 | -2.90% 10-K · filed 2021-03-10 | |
| 2017-12-31 | 0.50% 10-K · filed 2020-03-10 | |
| 2016-12-31 | -0.40% 10-K · filed 2019-03-12 | 1.40% 10-K · filed 2017-03-07 |
| 2015-12-31 | -0.50% 10-K · filed 2018-03-07 | 0.60% 10-K · filed 2017-03-07 |
| 2014-12-31 | 0.70% 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |